TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its implementations with two major cannabis cultivators in Israel, Springs Valley Cannabis LTD and UNIVO Pharmaceuticals (UNIVO), through Fluence’s ongoing partnership with REMY LTD (REMY), a leading, Israel-based horticultural lighting provider to the country’s growing agriculture industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005120/en/
Following the legalization of medical cannabis in 1993, Israel’s cannabis industry has flourished through in-depth research into efficient production and cultivation processes. With nearly 30 cultivators actively producing medical cannabis and dozens in planning stages, Israel is poised to meet and exceed demand for the estimated 100,000 medical cannabis users throughout the country. As legislation to legalize recreational cannabis use is evaluated, experts predict the industry will maintain its exponential growth trajectory.
“The rapid growth of the medical cannabis industry in Israel is a clear indicator of the recreational market’s potential,” said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. “To maintain the industry’s pace, cultivators must examine and invest in highly efficient production methods that yield consistent, high-quality cannabis products. Lighting plays one of the most crucial roles in that production process.”
Optimal lighting strategies for every phase of the cultivation value chain
Whether seed and variety breeding, cloning and growing plants, or the final cultivation of dense and full buds, each phase of the cannabis value chain requires optimized, curated lighting conditions. Fluence not only offers the industry’s leading LED lighting solutions, but provides evidence-based best practices to identify, implement and maintain the optimal lighting strategy at each phase of cannabis growth. Fluence’s research-backed cultivation methods supported by its team of horticulture specialists enable cannabis cultivators to achieve high-quality, consistent crops while conserving heating, ventilation and air conditioning costs.
REMY echoes Fluence’s cultivation philosophy and approach. Through their partnership, Fluence and REMY are serving Israel’s most innovative cultivators. Springs Valley Cannabis, located in Northern Israel, relies on Fluence’s LED technology in its large-scale, high-end indoor growing facility to ensure superior cannabis flowering within the company’s first cultivation environment.
“Lighting has a major effect on our high-end indoor farm's success,” said Yair Shaked, CEO at Springs Valley Cannabis. “We searched for a lighting partner that would support us and add value for the long run—that's why we chose to work with REMY and Fluence.”
UNIVO, a vertically integrated medical cannabis company covering all aspects of cultivation, manufacturing and distribution, leverages Fluence’s solutions in different stages of the growth cycle, including nursery, vegetative, flowering, mother stock, and research and development, where UNIVO clones and grows cannabis plants.
“Amit farm by UNIVO is one of the most sophisticated and technological farms in the Israeli cannabis industry, and after carefully reviewing the market, we decided to cooperate with Fluence to achieve the best premium cannabis flowers,” added Golan Bitton, CEO at UNIVO.
Continuous investment in new knowledge
“Amid Israel’s revered, dynamic high-tech industry, Fluence’s LED lighting technology is recognized as truly innovative. To maintain that position, we continuously invest in new knowledge and develop new techniques to best serve the world’s cultivators,” Bongartz added.
Fluence works closely with leading research institutions such as Wageningen University & Research to uncover new cultivation strategies and explore the influence of various light spectra on cannabis growth and development. Fluence’s collaborative research insights inform product innovations and provide growers with effective best practices to optimize plant growth.
“The job doesn’t stop when the light fixtures have been installed,” says Jörg Meyer-Brenken, Fluence’s lead account manager for cannabis in EMEA. “On the contrary, that’s when it starts and that’s where the Fluence and REMY teams add extraordinary value. REMY is a true, reliable partner. Their team combines deep lighting knowledge with years of experience in Israeli agriculture and horticulture, making REMY an ideal partner to help us reach a prominent position in this fast-growing market.”
“The end result for the cultivator is an agronomic lighting fixture, but the path to reach the optimal lighting strategy is driven by years of research and practical knowledge,” said Elad Toby, founder, CTO and chief business development officer for REMY. “There is huge opportunity in bringing Fluence’s groundbreaking knowledge to the Israeli medical cannabis market.”
For more information about Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, supervision and quality assurance of large-scale lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its showroom and headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom